Northern Trust’s Aardvark Therapeutics AARD Stock Holding History

Northern Trust’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$162K	Sell	28,080 -60,519	-68%	-$283K	﹤0.01%	3999
2026 Q1	$334K	Sell	88,599 -699	-0.8%	-$7.25K	﹤0.01%	3766
2025 Q4	$1.17M	Buy	89,298 +32,101	+56%	+$401K	﹤0.01%	3286
2025 Q3	$760K	Buy	57,197 +12,112	+27%	+$137K	﹤0.01%	3512
2025 Q2	$610K	Buy	45,085 +31,084	+222%	+$320K	﹤0.01%	3591
2025 Q1	$105K	Buy	+14,001	New	+$157K	﹤0.01%	4105

Other funds holding AARD

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Northern Trust's AARD Position: Q2 2026 in Review

Northern Trust reduced its Aardvark Therapeutics (AARD) stake by 68% in Q2 2026, selling an estimated $283K and leaving 28,080 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #3999.

Northern Trust first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.17M in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

Northern Trust held 28,080 shares of Aardvark Therapeutics worth $162K as of Q2 2026.
Northern Trust sold 60,519 Aardvark Therapeutics shares in Q2 2026, an estimated $283K.
Aardvark Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3999 holding.
Northern Trust first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
Northern Trust's Aardvark Therapeutics position peaked at $1.17M in Q4 2025.
71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.